Centessa IPO Presentation Deck

Lixivaptan: Potential for Best-in-Class Profile JYNARQUEⓇ (tolvaptan) REMS: Restricted distribution & prescription, frequent blood test monitoring for liver tox Initial data support thesis that lixivaptan avoids drug-induced liver injury (DILI) NON-CLINICAL EVIDENCE Tolvaptan causes DILI via 2 well-known hepatocyte injury mechanisms: disruption of bile acids homeostasis and mitochondrial dysfunction hepatocyte mitochondrion MRP4 bile salts DM-4103 tolvaptan BSEP • Long-lived metabolite of tolvaptan contributes to toxicity • Lixivaptan does not share metabolites with tolvaptan IN SILICO EVIDENCE DILISym (highly predictive quantitative systems toxicology tool) • Correctly predicted DILI potential of numerous drug pairs • Accurately reproduced liver toxicity of tolvaptan • Predicted lixivaptan not likely to cause DILI and may be better tolerated than tolvaptan with respect to liver tox Tolvaptan Lixivaptan ALT > 3x ULN DILIsym Simulated 7.9% 0.0% PALLADIO BIOSCIENCES Actual Clinical 4.4% to 5.6% Hy's Law Cases DILISym Simulated Yes No Actual Clinical Yes CENTESSA 12

View entire presentation